Light Therapy for Obsessive-compulsive Disorder (OCD)
ConditionOCD
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age17-35
SponsorWashington University School of Medicine
About this trial
The goal of this clinical trial is to test whether light therapy is effective for reducing symptoms in young adults with OCD and late bedtimes (1am or later). The main question\[s\] it aims to answer are:
Does light therapy reduce OCD symptoms? Does light therapy advance the circadian clock? If there is a comparison group: Researchers will compare a higher dose of light therapy to a lower dose to see if dose amount affects symptom reduction.
Participants will asked to:
1. Wear light therapy glasses for 1 hour each morning and complete a daily light therapy log for 5 weeks 2. Track their sleep every day with a wearable monitor and an electronic sleep diary for 5 weeks 3. Complete a 1-time assessment of sensitivity to light exposure 4. Complete self-report measures of OCD 4 times/day at baseline (2 weeks), mid-treatment (1 week), and end of treatment (1 week)
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Primary DSM-5 OCD diagnosis
Bedtime 0100 or later
Age 18-35
English speaking
Disqualifiers
Subjects must not be currently participating in another research study that would influence their participation in our study.
Diagnostic status
Treatment status
Night shift work or travel more than 1 time zone outside of Central Standard Time (CST) in the past month
Trial design
Design model
Parallel
Treatments tested in this trial
Light therapy
Behavioral5 weeks of light therapy administered via wearable light therapy glasses worn for 1 hour each morning after awakening.
Treatment groups
40 Participants
are divided into 2 treatment groupsGroup A: Higher doseExperimental treatment 1 intervention
Group B: Lower doseSham comparator 1 intervention
Trial outcomes
Primary outcomes
1
Yale Brown Obsessive-Compulsive Scale (YBOCS)
A retrospective clinical interview of OCD symptom severity. Score range from 0 to 40 and higher scores indicate more severe OCD symptoms.
Time frame
Administered at baseline, in treatment week 3, and post-treatment (3 administrations over 7 weeks)2
Daily Perseverative Thinking Questionnaire
Self-report measure of momentary transdiagnostic repetitive negative thinking. Score range from 6 to 42 and higher scores indicate more severe repetitive negative thinking.
Time frame
Administered 4 times/day for 2 weeks at baseline, 4 times/day for 1 week in treatment week 3, and 4 times/day for 1 week in treatment week 5Secondary outcomes
1
Circadian melatonin phase
Dim light melatonin onset assessed by taking hourly saliva samples in dim light conditions for 10 hours beginning 7 hours before typical bedtime and ending 2 hours after typical bedtime.
Time frame
At baseline and post-treatment (after 5 weeks of treament)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov